Linked Life Data

17215530

Source:http://linkedlifedata.com/resource/pubmed/id/17215530

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-1-11
pubmed:databankReference
pubmed:abstractText
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1533-4406
pubmed:author
pubmed:copyrightInfo
Copyright 2007 Massachusetts Medical Society.
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
356
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-34
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Sorafenib in advanced clear-cell renal-cell carcinoma.
pubmed:affiliation
Department of Medicine, Institut Gustave Roussy, Villejuif, France. escudier@igr.fr
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III